Article
USA300 and USA500 clonal lineages of Staphylococcus aureus do not produce a capsular polysaccharide due to conserved mutations in the cap5 locus.
mBio - 7 Apr 2015
Boyle-Vavra Susan, Li Xue, Alam Md Tauqeer, Read Timothy D, Sieth Julia, Cywes-Bentley Colette, Dobbins Ginette, David Michael Z, Kumar Neha, Eells Samantha J, Miller Loren G, Boxrud David J, Chambers Henry F, Lynfield Ruth, Lee Jean C, Daum Robert S
Abstract excerpt
UNLABELLED: The surface capsular polysaccharide (CP) is a virulence factor that has been used as an antigen in several successful vaccines against bacterial pathogens. A vaccine has not yet been licensed against Staphylococcus aureus, although two multicomponent vaccines that contain CP antigens are in clinical trials. In this study, we evaluated CP production in USA300 methicillin-resistant S. aureus (MRSA)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
